title: Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants.
abstract: BACKGROUND
  Nelfinavir dosed at approximately 20 to 30 mg/kg three times a day (TID) in older children provides exposure similar to 750 mg TID in adults. However, the pharmacokinetics (PK) of nelfinavir in infants who are < 2 years of age is not well-described. The objective of this study was to determine the pharmacokinetics of nelfinavir in infants < 2 years of age.
  
  
  METHODS
  Nelfinavir concentrations were evaluated in 22 HIV-infected infants between 15 days and 2 years of age receiving nelfinavir as part of Pediatric ACTG Study 356. Nelfinavir therapy was initiated at approximately 25 mg/kg TID (n = 18) or approximately 55 mg/kg twice a day (n = 4) and given in combination with nevirapine, stavudine and lamivudine. PK samples were obtained predose and 1.5 and 4 h postdose at approximately 6-month intervals. Eight infants (all < or = 3 months of age) also had intensive PK samples collected at Week 1.
  
  
  RESULTS
  The median apparent clearance in the infants with intensive pharmacokinetic sampling was 2.7 liters/h/kg (range, 1.8 to > or = 10) and was similar between twice a day and TID dosing cohorts. Overall nelfinavir concentrations at all collection times were lower in these infants than previously reported in older pediatric patients.
  
  
  CONCLUSIONS
  Nelfinavir concentrations in infants are highly variable and lower than those seen in adult or older pediatric populations receiving labeled dosing. Therefore it is necessary to further evaluate nelfinavir safety, effectiveness and pharmacokinetics at higher doses than used among other pediatric populations.
authors.affiliation: Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA.
authors.forename: E V
authors.initials: EV
authors.lastname: Capparelli
authors.forename: J L
authors.initials: JL
authors.lastname: Sullivan
authors.forename: L
authors.initials: L
authors.lastname: Mofenson
authors.forename: E
authors.initials: E
authors.lastname: Smith
authors.forename: B
authors.initials: B
authors.lastname: Graham
authors.forename: P
authors.initials: P
authors.lastname: Britto
authors.forename: M I
authors.initials: MI
authors.lastname: Becker
authors.forename: D
authors.initials: D
authors.lastname: Holland
authors.forename: J D
authors.initials: JD
authors.lastname: Connor
authors.forename: K
authors.initials: K
authors.lastname: Luzuriaga
mesh_terms: D019380:Anti-HIV Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000502:physiology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D019888:Nelfinavir / Q000493:pharmacokinetics*; D012367:RNA, Viral / Q000097:blood; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D019888:Nelfinavir